Category : Search result: Lupin


Lupin: Undervalued Pharma Giant at 21x P/E?

Lupin stocks trade at 21.7x P/E despite record earnings and 80 new products pipeline. Discover why this pharma giant might be undervalued and poised for next growth cycle with biosimilars and complex generics.

LIC, Ola Electric, Lupin Q2 Results Today

Investors brace for a high-stakes earnings Thursday as insurance giant LIC, EV pioneer Ola Electric, and pharma major Lupin headline over 20 companies declaring Q2 FY2025 results. Get expert insights on what to expect.

Page 1 of 1